.png)
We are honored to announce that Neumirna Therapeutics has received the 2024 CURE Epilepsy Catalyst Award. This generous funding ($250,000 over two years) will help us advance critical biomarker research needed to develop and deliver our lead candidate NMT.001 to patients with drug-resistant epilepsy.
"CURE and Neumirna Therapeutics are united by a shared mission: to drive forward disease-modifying therapies with the potential to cure epilepsy," said our founder and PI on the project, Dr. Henrik Klitgaard. "Biomarkers are essential because they ensure we match the right drug to the right patient. Thanks to CURE’s support, we can pursue both drug and biomarker discovery – bringing us closer to transforming how epilepsy is treated."
CURE Epilepsy is the leading nonprofit epilepsy research organization solely dedicated to funding groundbreaking research with the goal of finding a cure. The Catalyst Award is given to cutting-edge, novel research projects that seek to accelerate treatments, develop tools to improve outcomes, and get us to cures so that we can live in a world free of seizures.
We are grateful to CURE Epilepsy and their sponsors for believing in our vision and our ability to turn funding into tangible benefits for patients.
.svg)
